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ABSTRACT: Anhydrouridines react with aliphatic amines to give N-alkyl isocytosines, but reported procedures often demand very long 
reaction times, and can be low-yielding, with narrow scope. A modified procedure for such reactions has been developed, using microwave 
irradiation, significantly reducing reaction time and allowing facile access to a diverse range of novel nucleosides on gram-scale. The method 
has been used to prepare a precursor to a novel analogue of lysidine, a naturally occurring iminonucleoside found in tRNA. 
Non-coded (‘unnatural’) nucleoside analogues are privileged 
chemical motifs, possessing a diverse range of biological and clini-
cal properties. Most nucleoside drug candidates contain modified 
heterocyclic components but modification to the native ribose core 
can also confer significant biological activity, and 2’-modified nu-
cleosides are found at the heart of marketed antisense oligonucleo-
tide1 medications, including mipomersen (Kynamro®, used to treat 
homozygous familial hypercholesterolemia) and nusinersen 
(Spinraza®, for spinal muscular atrophy). 2’-Modified mononucleo-
sides also exhibit biological potency, and arabino-configured nu-
cleosides Cytarabine (ara-C 1, acute myeloid and lymphocytic 
leukaemias, and lymphomas; Figure 2), Clevudine (2, hepatitis B) 
and Fludarabine (3, chronic lymphocytic leukaemia, non-Hodgkin 
lymphoma) are used in the clinic, leading to great interest in meth-
ods for synthesis of this class of compound.2, 3 In addition to thera-
peutic significance, modified nucleosides are also of great utility as 
structural probes and as chemical start points for functional syn-
thetic polynucleotides. Arabino-configured antisense systems have 
been prepared and shown to posses interesting properties,4 and 
aminated arabino-isocytosines 4  are also biologically active nucleo-
side analogues, possessing anti-cancer activity,5 and as precursors to 
polynucleotides able to form duplexes with isoG-containing se-
quences.6 As part of a research program directed towards synthesis 
and testing of novel catalytic polynucleotides possessing both mod-
ified base and ribose motifs, compounds rarely reported in the liter-
ature, we sought a synthetic entry to arabino-configured isocyto-


































































Figure  1 .  arabino-Nucleosides: privileged chemical motifs 
 In addition, for similar purposes, we also sought access to arabi-
no-configured analogues of the naturally occurring tRNA nucleo-
side Lysidine 5 , as potential inhibitors of lysidine synthetase.7 
We envisaged entry to arabino-isocytosines, including the previ-
ously unreported lysidine analogue 6 , by means of ring-opening of 
2, 3’-anhydrouridines 7  by aliphatic amines (Figure 2): thus, reac-
tion of a suitably protected lysine 8  would directly give the protect-
ed lysidine analogue. However, we found existing methods capri-
cious and low-yielding and so sought an alternative entry to these 
non-coded nucleoside analogues; we report here a modified proce-
dure which ameliorates these problems, delivering the target nucle-
osides on gram-scale, and representing a significant advance over 



























F igure  2 .  Arabino-ketolysidine synthesis: s trategy 
 
The ring-opening of anhydrouridine by ammonia was first re-
ported by Todd et al;8 the method was later refined9 and broadened 
in scope, to include higher amines.10 In general, the ring-opening of 
anhydrouridine with alkylamines to give ara-isocytosines is a slow 
process,11 with reactions typically taking several days to reach com-
pletion (e.g., ring-opening of anhydrouridine by cyclohexylamine 
takes 32 days to reach completion10). Moreover, the isolation of 
aminated products is inefficient, with post-reaction derivatization 
of the unprotected product necessary to allow reasonable yields to 
be achieved.8 Prior protection of the 5’-hydroxyl group directly 
delivers tractable products, but does not noticeably improve the 
rate of reaction. The use of microwave irradiation to accelerate 
reactions, in particular those performed in polar solvents, is a con-
temporary paradigm, and we envisaged that this would be a valua-
ble method to accelerate the ring-opening of anhydronucleosides 
by amines. After a screen of reaction conditions, we were, therefore, 
gratified to observe that anhydrouridines 7b-d reacted with me-
thylamine and nbutylamine in THF at 80 ˚C at 300 W to give the 
aminated products, arabino-isocytosines 4ba, 4ca , 4cb and 4db, 
in good yields, after only 1 hour (Table 1). The reaction with me-
thylamine had not been reported in the literature, presumably due 
to the volatility of the amine component. 
Although the ring-opened products proved stable to chromatog-
raphy, showing little tendency to return to the anhydro starting 
material, the products could more conveniently be isolated by pre-
cipitation from the crude reaction medium.  
Table  1 .  Nucleoside amination by ring-opening of anhydrouri-


















7a: R1 = R2 = H; 7b: R1 = TBS, R2 = H; 
7c: R1 = R2 = TBS; 7d: R1 = TBDPS, R2 = H
R1 = R2 = H
4aa: R = Me; 4ab: R = nBu
R1 = TBS, R2 = H; 
4ba: R = Me; 4bb: R = nBu
R1 = R2 = TBS,; 
4ca: R = Me; 4cb: R = nBu
R1 = TBDPS, R2 = H
4db: R = nBu
 
7  R condit ions  react ion 
t ime/h 
product  y ie ld/% 
7a Me DMF, 7 eq. amine, 
rta10 
N/A 4aa N/A 
7a nBu DMF, 7 eq. amine, 
rta 
72 4ab 71b 
7b12 Me THF 10 eq. amine, 
µW, 80 ˚C 
1 4ba 89 
7c 12 Me THF 10 eq. amine, 
µW, 80 ˚C 
1 4ca  65 
7b nBu THF 10 eq. amine, 
µW, 120 ˚C 
1 4bb mixture 
7c  nBu THF 10 eq. amine, 
µW, 80 ˚C 
0.5 4cb 55 
7c  nBu THF 10 eq. amine, 
µW, 120 ˚C 
0.5 4cb 0 
7c  nBu THF 10 eq. amine, 
ZnCl2, µW, 120 ˚C 
0.5 4cb 0 
7d 13 nBu THF 10 eq. amine, 
µW, 80 ˚C 
1 4db 68 
a Ref.10; b Yield of corresponding triacetate 
Thus the microwave-mediated procedure reduced the reaction 
time by 97%; when compared to the reported procedure10 using 
other amines, the increase in the rate of reaction was even more 
striking (Table 2). The use of THF rather than a high-boiling polar 
solvent (such as DMF10) also represents a significant simplification 
in the process. 
 
The process can be applied to a range of aliphatic amines (Figure 
3), delivering arabino-2-(alkyl)amino isocytosines in good yields. 
The simplicity of the method enables gram-scale reactions to be 
carried out in short order, and the ability to isolate  pure products 


























7a: R1 = R2 = H; 7d: R1 = TBDPS, R2 = H
R1 = R2 = H
4ab: R = nBu; 4ac: R = Allyl 
4ad: R = Bn; 4ae: R = cHex
R1 = TBDPS, R2 = H
4db: R = nBu; 4dc: R = Allyl 
4dd: R = Bn; 4de: R = cHex
 
7  R condit ions  reaction 
t ime/h 
product  yield/% 
7a  nBu DMF, 7 eq. 
amine, rt) 10 
36 4ab 71a 
7d nBu THF 10 eq.  
amine,  µW , 
80 ˚C 
1 4db 68 
7a  Allyl DMF, 7 eq. 
amine, rt10 
48 4ac  77a 
7d Al ly l  THF 10 eq.  
amine,  µW , 
80 ˚C 
1 4dc 66 
7a  Benzyl DMF, 7 eq. 
amine, rt10 
180 4ad 90a 
7d Benzyl  THF 10 eq.  
amine,  µW , 
80 ˚C 
1  4dd 56 
7a  cHex DMF, 7 eq. 
amine, rt10 
384 4ae 72a 
7d cHex THF 10 eq.  
amine,  µW , 
80 ˚C 
1  4de 51 
a Yield of corresponding triacetate 
Armed with a new and efficient entry into 2-(alkyl)amino isocy-
tosine nucleosides, we turned our attention to our original target 
molecule, ketocytosine analogue 6 , and we were delighted to ob-
serve that reaction of lysine derivative 8  with anhydrouridine 7d 
delivered the key product 9  (a protected precursor to 6) in excel-























THF, µW, 80˚C, 1 h
 
Schem e 1.  Synthesis of novel ketolysidine derivative 9 . 
In summary, we have reported an improved method for amina-
tion of 2,2’-anhydrouridine, enabling a practical and high yielding 
entry to a range of 2-aminated nucleosides. We are currently en-
























































































































F igure  3 .  Amination of 5’-O-TBDPS-2,2’-Anhydrouridine: 
scope 
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Experimental details and associated spectral data. The Supporting 
Information is available free of charge on the ACS Publications web-
site. 
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